{"data":{"filter_options":{"titles":[{"name":"Managing Partner Atlanta Office","value":"Managing Partner Atlanta Office"},{"name":"Partner","value":"Partner"},{"name":"Partner / Head of Pro Bono","value":"Partner / Head of Pro Bono"},{"name":"Partner / Chief Operating Officer","value":"Partner / Chief Operating Officer"},{"name":"Partner / General Counsel","value":"Partner / General Counsel"},{"name":"Partner / Dir. E-Discovery Ops","value":"Partner / Dir. E-Discovery Ops"},{"name":"Partner / Chairman, Saudi Arabia Practice","value":"Partner / Chairman, Saudi Arabia Practice"},{"name":"K\u0026S Talent Partner","value":"K\u0026S Talent Partner"},{"name":"Partner / Chief Human Resources Officer","value":"Partner / Chief Human Resources Officer"},{"name":"Chairman","value":"Chairman"},{"name":"Senior Counsel","value":"Senior Counsel"},{"name":"Associate Director, E-Discovery Operations","value":"Associate Director, E-Discovery Operations"},{"name":"Counsel","value":"Counsel"},{"name":"Senior Associate","value":"Senior Associate"},{"name":"Associate","value":"Associate"},{"name":"Senior Attorney","value":"Senior Attorney"},{"name":"Senior Lawyer","value":"Senior Lawyer"},{"name":"Attorney","value":"Attorney"},{"name":"Senior Counsel and Policy Advisor","value":"Senior Counsel and Policy Advisor"},{"name":"Managing Director - Capital Solutions","value":"Managing Director - Capital Solutions"},{"name":"Senior Government Relations Advisor","value":"Senior Government Relations Advisor"},{"name":"Associate General Counsel","value":"Associate General Counsel"},{"name":"Senior Advisor","value":"Senior Advisor"},{"name":"Patent Agent","value":"Patent Agent"},{"name":"Consultant","value":"Consultant"},{"name":"Government Relations Advisor","value":"Government Relations Advisor"},{"name":"Chief of Lateral Partner Recruiting \u0026 Integration","value":"Chief of Lateral Partner Recruiting \u0026 Integration"},{"name":"Chief Financial Officer","value":"Chief Financial Officer"},{"name":"Chief Information Officer","value":"Chief Information Officer"},{"name":"Chief Revenue Officer","value":"Chief Revenue Officer"},{"name":"Chief Recruiting Officer","value":"Chief Recruiting Officer"},{"name":"Chief Lawyer Talent Development Officer","value":"Chief Lawyer Talent Development Officer"},{"name":"Chief Marketing Officer","value":"Chief Marketing Officer"},{"name":"Tax Consultant","value":"Tax Consultant"},{"name":"Director of Community Affairs","value":"Director of Community Affairs"},{"name":"Director of Facilities \u0026 Admin Operations","value":"Director of Facilities \u0026 Admin Operations"},{"name":"Senior Office Manager","value":"Senior Office Manager"},{"name":"Director of Operations","value":"Director of Operations"},{"name":"Pro Bono Deputy","value":"Pro Bono Deputy"},{"name":"Director of Office Operations","value":"Director of Office Operations"},{"name":"Director of Operations Europe","value":"Director of Operations Europe"},{"name":"Law Clerk","value":"Law Clerk"},{"name":"Deputy General Counsel","value":"Deputy General Counsel"}],"schools":[{"name":"(Commercial Law), in front of Monash University, Australia","value":3045},{"name":"Aberystwyth University","value":3004},{"name":"Albany Law School","value":2118},{"name":"American University Washington College of Law","value":3042},{"name":"American University, Washington College of Law","value":3024},{"name":"Appalachian School of Law","value":2891},{"name":"Ateneo de Manila University","value":2914},{"name":"Ave Maria School of Law","value":2892},{"name":"Baylor University School of Law","value":181},{"name":"Benjamin N. Cardozo School of Law","value":2619},{"name":"Binghamton University","value":3002},{"name":"Boston College Law School","value":245},{"name":"Boston University School of Law","value":247},{"name":"BPP Law School Leeds","value":2642},{"name":"BPP Law School London","value":2782},{"name":"BPP University","value":2984},{"name":"Brooklyn Law School","value":2705},{"name":"Cairo University, Law School","value":2962},{"name":"California Western School of Law","value":315},{"name":"Capital University Law School","value":327},{"name":"Case Western Reserve University School of Law","value":345},{"name":"Cecil C. Humphreys School of Law","value":2235},{"name":"Chapman University School of Law","value":377},{"name":"Charleston School of Law","value":2910},{"name":"City Law School, London","value":2998},{"name":"City Law School","value":2857},{"name":"Clark University","value":3006},{"name":"Cleveland-Marshall College of Law","value":426},{"name":"Columbia University School of International and Public Affairs","value":3008},{"name":"Columbia University School of Law","value":485},{"name":"Columbia University","value":3126},{"name":"Columbus School of Law, Catholic University of America","value":3010},{"name":"Columbus School of Law","value":350},{"name":"Concord Law School of Kaplan University","value":1026},{"name":"Cornell Law School","value":512},{"name":"Creighton University School of Law","value":518},{"name":"Creighton University","value":3025},{"name":"Cumberland School of Law","value":1759},{"name":"CUNY School of Law","value":2893},{"name":"David A. Clarke School of Law","value":2399},{"name":"Deakin University School of Law","value":2907},{"name":"DePaul University College of Law","value":565},{"name":"DePaul University College of Law","value":3060},{"name":"Dickinson School of Law","value":2719},{"name":"Drake University Law School","value":609},{"name":"Duke University School of Law","value":613},{"name":"Duquesne University School of Law","value":614},{"name":"Dwayne O. Andreas School of Law","value":173},{"name":"Edinburgh Law School","value":3160},{"name":"Emory University School of Law","value":659},{"name":"ESADE Business and Law School – Universidad Ramon Llull","value":3215},{"name":"Fachseminare von Fürstenberg","value":2918},{"name":"Faculté Libre de Droit, Université Catholique de Lille","value":3055},{"name":"Faculty of Law, University of Zagreb","value":2983},{"name":"Faculty of Law","value":2944},{"name":"Faculty of Law","value":3039},{"name":"Federal University of Rio de Janeiro","value":3022},{"name":"Federal University of Rio Grande do Sul School of Law (Brazil)","value":3062},{"name":"Florida A\u0026M University College of Law","value":699},{"name":"Florida Coastal School of Law","value":2894},{"name":"Florida International College of Law","value":707},{"name":"Florida State University College of Law","value":720},{"name":"Fordham University School of Law","value":722},{"name":"Franklin Pierce Law Center","value":734},{"name":"Friedrich-Schiller-Universität Jena","value":3015},{"name":"George Mason University School of Law","value":752},{"name":"George Washington University Law School","value":753},{"name":"Georgetown University Law Center","value":755},{"name":"Georgia State University College of Law","value":761},{"name":"Ghent Law School","value":2793},{"name":"Golden Gate University School of Law","value":770},{"name":"Gonzaga University School of Law","value":772},{"name":"Graduate Institute of International and Development Studies, Geneva","value":2997},{"name":"Hamline University School of Law","value":811},{"name":"Harvard Law School","value":824},{"name":"Hebrew University of Jerusalem Faculty of Law","value":2994},{"name":"Hofstra University School of Law","value":858},{"name":"Howard University School of Law","value":872},{"name":"Huazhong University of Science and Technology","value":3016},{"name":"Humboldt University of Berlin","value":3012},{"name":"Indiana University School of Law","value":2711},{"name":"Indiana University School of Law","value":890},{"name":"International Association of Privacy Professionals","value":3009},{"name":"J. Reuben Clark Law School","value":262},{"name":"Jacob D. Fuchsberg Law Center","value":2084},{"name":"James Cook University of North Queensland","value":3034},{"name":"Jean Moulin University Lyon 3, France","value":2938},{"name":"Johns Hopkins Bloomberg School of Public Health","value":2992},{"name":"Justus-Liebig-Universität Gießen Rechtswissenschaft (Germany)","value":3063},{"name":"Kansas City School of Law","value":2247},{"name":"Keio University","value":2968},{"name":"Kent College of Law","value":883},{"name":"Kline School of Law","value":611},{"name":"KU Leuven","value":3007},{"name":"Levin College of Law","value":2189},{"name":"Lewis and Clark Law School","value":1089},{"name":"Liberty University School of Law","value":1094},{"name":"Lincoln College of Law","value":2253},{"name":"LL.M. in International Crime and Justice UNICRI","value":2937},{"name":"Loyola Law School","value":2895},{"name":"Loyola University Chicago School of Law","value":1135},{"name":"Loyola University New Orleans College of Law","value":1136},{"name":"Marquette University Law School","value":1176},{"name":"McGeorge School of Law","value":2402},{"name":"McGill University","value":2659},{"name":"Melbourne Law School","value":2899},{"name":"Mercer University Walter F. George School of Law","value":1221},{"name":"Mexico Autonomous Institute of Technology","value":2996},{"name":"Michael E. Moritz College of Law","value":2728},{"name":"Michigan State University College of Law","value":1245},{"name":"Mississippi College School of Law","value":1285},{"name":"Moscow State University","value":2815},{"name":"National and Kapodistrian University of Athens","value":3032},{"name":"National Law University Jodhpur","value":3020},{"name":"National University of Singapore, Faculty of Law","value":2662},{"name":"New England School of Law","value":2886},{"name":"New York Law School","value":1403},{"name":"New York University School of Law","value":1406},{"name":"Norman Adrian Wiggins School of Law","value":323},{"name":"North Carolina Central University School of Law","value":1417},{"name":"Northeastern University School of Law","value":1430},{"name":"Northern Illinois University College of Law","value":1432},{"name":"Northwestern Pritzker School of Law","value":1451},{"name":"Notre Dame Law School","value":2278},{"name":"Ohio Northern University Law School","value":3036},{"name":"Oklahoma City University School of Law","value":1487},{"name":"Osgoode Hall Law School","value":3124},{"name":"Pace University School of Law","value":1516},{"name":"Panteion University","value":3033},{"name":"Paul M. Hebert Law Center","value":2713},{"name":"Pennsylvania State University, Dickinson School of Law","value":1562},{"name":"Pepperdine University School of Law","value":1570},{"name":"Pettit College of Law","value":1473},{"name":"Pontificia Universidad Catolica de Chile","value":3203},{"name":"Pontificia Universidad Catolica del Peru","value":3011},{"name":"Pontificia Universidad Javeriana","value":3013},{"name":"Pontificia Universidade Catolica de Sao Paulo","value":3095},{"name":"Prince Sultan University College of Law","value":3167},{"name":"Queens College, Cambridge","value":3003},{"name":"Quinnipiac University School of Law","value":1626},{"name":"Ralph R. Papitto School of Law","value":1686},{"name":"Regent University School of Law","value":1649},{"name":"Rice University","value":3043},{"name":"Ruprecht-Karls-Universität Heidelberg","value":3049},{"name":"Rutgers University School of Law-Newark","value":1699},{"name":"Rutgers University School of Law","value":1697},{"name":"S.J. Quinney College of Law","value":2408},{"name":"Saint Louis University School of Law","value":1732},{"name":"Salmon P. Chase College of Law","value":1433},{"name":"Sandra Day O'Connor College of Law","value":103},{"name":"Santa Clara University School of Law","value":1771},{"name":"Seattle University School of Law","value":1787},{"name":"Seton Hall University School of Law","value":1790},{"name":"Shepard Broad Law Center","value":1460},{"name":"South Texas College of Law","value":2721},{"name":"Southern Illinois University School of Law","value":1849},{"name":"Southern Methodist University Dedman School of Law","value":1852},{"name":"Southern University Law Center","value":1857},{"name":"Southwestern Law School","value":1876},{"name":"St. John's University School of Law","value":2724},{"name":"St. Mary's University School of Law","value":1896},{"name":"St. Thomas University School of Law","value":1746},{"name":"Stanford Law School","value":1904},{"name":"Stetson University College of Law","value":1910},{"name":"Sturm College of Law","value":2184},{"name":"Suffolk University Law School","value":1921},{"name":"Syracuse University College of Law","value":1956},{"name":"Temple University Beasley School of Law","value":1974},{"name":"Texas A\u0026M School of Law","value":1980},{"name":"Texas Tech University School of Law","value":1994},{"name":"Texas Wesleyan University School of Law","value":1996},{"name":"The College of Law Australia","value":3091},{"name":"The College of Law, London","value":2935},{"name":"The John Marshall Law School","value":2034},{"name":"The Judge Advocate General's Legal Center and School","value":2896},{"name":"The Ohio State University Moritz College of Law","value":2990},{"name":"The University of Akron School of Law","value":2143},{"name":"The University of Alabama School of Law","value":2045},{"name":"The University of Birmingham, U.K.","value":2796},{"name":"The University of Iowa College of Law","value":2206},{"name":"The University of Texas School of Law","value":2055},{"name":"The University of Tulsa College of Law","value":2407},{"name":"Thomas Jefferson School of Law","value":685},{"name":"Thomas M. Cooley Law School","value":2729},{"name":"Thurgood Marshall School of Law","value":1992},{"name":"Tianjin University of Commerce","value":2995},{"name":"Tulane University Law School","value":2113},{"name":"UC Davis School of Law","value":2160},{"name":"UCLA School of Law","value":2162},{"name":"Universidad Católica de Honduras","value":2916},{"name":"Universidad Francisco Marroquin","value":3090},{"name":"Universidad Panamericana","value":2904},{"name":"Universidad Torcuato di Tella","value":3035},{"name":"Universidade de São Paulo, Faculdade de Direito","value":3028},{"name":"Universidade Presbiteriana Mackenzie","value":2977},{"name":"Università Commerciale Luigi Bocconi","value":3135},{"name":"University at Buffalo Law School","value":1928},{"name":"University College Dublin Law School","value":2900},{"name":"University of Alberta Faculty of Law","value":3088},{"name":"University of Amsterdam","value":2980},{"name":"University of Arizona, James E. Rogers College of Law","value":2149},{"name":"University of Arkansas School of Law","value":2154},{"name":"University of Baltimore School of Law","value":2156},{"name":"University of California College of the Law","value":3196},{"name":"University of California Hastings College of Law","value":2158},{"name":"University of California Irvine School of Law","value":2161},{"name":"University of California, Berkeley, School of Law","value":2159},{"name":"University of California, Davis","value":3019},{"name":"University of Cambridge, U.K","value":2991},{"name":"University of Canterbury","value":2981},{"name":"University of Central Florida","value":3027},{"name":"University of Chester Law School","value":3005},{"name":"University of Chicago Law School","value":2174},{"name":"University of Chicago","value":3038},{"name":"University of Cincinnati College of Law","value":2175},{"name":"University of Colorado School of Law","value":2177},{"name":"University of Connecticut School of Law","value":2180},{"name":"University of Dayton School of Law","value":2182},{"name":"University of Detroit Mercy School of Law","value":2185},{"name":"University of East Anglia","value":3000},{"name":"University of Florida, Levin College of Law","value":3188},{"name":"University of Georgia School of Law","value":2190},{"name":"University of Houston Law Center","value":2197},{"name":"University of Hull","value":3040},{"name":"University of Idaho College of Law","value":2201},{"name":"University of Illinois College of Law","value":2204},{"name":"University of Kansas School of Law","value":2208},{"name":"University of Kentucky College of Law","value":2210},{"name":"University of La Verne College of Law","value":2211},{"name":"University of Law, London","value":2999},{"name":"University of Lethbridge","value":3030},{"name":"University of Louisville Brandeis School of Law","value":2214},{"name":"University of Maine School of Law","value":2391},{"name":"University of Maryland School of Law","value":2224},{"name":"University of Miami School of Law","value":2236},{"name":"University of Michigan Law School","value":2237},{"name":"University of Minnesota Law School","value":2243},{"name":"University of Mississippi School of Law","value":2244},{"name":"University of Missouri School of Law","value":2246},{"name":"University of Montana School of Law","value":2048},{"name":"University of Nebraska College of Law","value":2744},{"name":"University of New Mexico School of Law","value":2262},{"name":"University of North Carolina School of Law","value":2266},{"name":"University of North Dakota School of Law","value":2271},{"name":"University of Oklahoma Law Center","value":2747},{"name":"University of Oregon School of Law","value":2281},{"name":"University of Pennsylvania Law School","value":2282},{"name":"University of Pittsburgh School of Law","value":2354},{"name":"University of Richmond School of Law","value":2370},{"name":"University of San Diego School of Law","value":2377},{"name":"University of San Francisco School of Law","value":2378},{"name":"University of South Carolina School of Law","value":2750},{"name":"University of South Dakota School of Law","value":2387},{"name":"University of Southern California Gould School of Law","value":3051},{"name":"University of St. Thomas School of Law","value":2751},{"name":"University of Sydney Law School","value":3031},{"name":"University of Tennessee College of Law","value":2051},{"name":"University of the West of England, Bristol","value":3001},{"name":"University of Toledo College of Law","value":2406},{"name":"University of Toronto","value":2912},{"name":"University of Utah","value":3026},{"name":"University of Virginia School of Law","value":2410},{"name":"University of Washington School of Law","value":2412},{"name":"University of Wisconsin Law School","value":2419},{"name":"University of Wyoming College of Law","value":2429},{"name":"University of Zürich","value":3037},{"name":"University Paris Dauphine","value":2976},{"name":"University Paris II Assas","value":2975},{"name":"University Paris II Assas","value":3052},{"name":"USC Gould School of Law","value":2389},{"name":"Utrecht University","value":3085},{"name":"Valparaiso University School of Law","value":2441},{"name":"Vanderbilt University School of Law","value":2442},{"name":"Vermont Law School","value":2451},{"name":"Villanova University School of Law","value":2454},{"name":"Wake Forest University School of Law","value":2471},{"name":"Washburn University School of Law","value":2482},{"name":"Washington and Lee University School of Law","value":2484},{"name":"Washington College of Law","value":61},{"name":"Washington University in St. Louis School of Law","value":2489},{"name":"Wayne State University Law School","value":2493},{"name":"West Virginia University College of Law","value":2517},{"name":"Western New England College School of Law","value":2528},{"name":"Western State College of Law","value":2897},{"name":"Wharton School of Business","value":3044},{"name":"Whittier Law School","value":2564},{"name":"Widener University Delaware Law School","value":2569},{"name":"Willamette University College of Law","value":2573},{"name":"William \u0026 Mary Law School","value":462},{"name":"William H. Bowen School of Law","value":2150},{"name":"William Mitchell College of Law","value":2758},{"name":"William S. Boyd School of Law","value":2256},{"name":"William S. Richardson School of Law","value":2195},{"name":"Wilmington University","value":2993},{"name":"Yale Law School","value":2605}],"offices":[{"name":"Abu Dhabi","value":13},{"name":"Atlanta","value":1},{"name":"Austin","value":12},{"name":"Brussels","value":23},{"name":"Charlotte","value":8},{"name":"Chicago","value":21},{"name":"Dallas","value":28},{"name":"Denver","value":22},{"name":"Dubai","value":6},{"name":"Frankfurt","value":9},{"name":"Geneva","value":15},{"name":"Houston","value":4},{"name":"London","value":5},{"name":"Los Angeles","value":19},{"name":"Miami","value":25},{"name":"New York","value":3},{"name":"Northern Virginia","value":24},{"name":"Paris","value":14},{"name":"Riyadh","value":27},{"name":"Sacramento","value":20},{"name":"San Francisco","value":10},{"name":"Silicon Valley","value":11},{"name":"Singapore","value":16},{"name":"Sydney","value":26},{"name":"Tokyo","value":18},{"name":"Washington, D.C.","value":2}],"capabilities":[{"name":"Corporate, Finance and Investments","value":"cg-1"},{"name":"Activist Defense","value":72},{"name":"Capital Markets","value":26},{"name":"Construction and Procurement","value":40},{"name":"Corporate Governance","value":27},{"name":"Emerging Companies and Venture Capital","value":80},{"name":"Employee Benefits and Executive Compensation","value":28},{"name":"Energy and Infrastructure Projects","value":35},{"name":"Financial Restructuring","value":10},{"name":"Fund Finance","value":134},{"name":"Global Human Capital and Compliance ","value":121},{"name":"Investment Funds and Asset Management","value":78},{"name":"Leveraged Finance","value":29},{"name":"Mergers and Acquisitions (M\u0026A)","value":32},{"name":"Middle East and Islamic Finance and Investment","value":31},{"name":"Private Equity","value":33},{"name":"Public Companies","value":126},{"name":"Real Estate","value":36},{"name":"Structured Finance and Securitization","value":82},{"name":"Tax","value":37},{"name":"Technology Transactions","value":115},{"name":"Government Matters","value":"cg-2"},{"name":"Antitrust","value":1},{"name":"Data, Privacy and Security","value":6},{"name":"Environmental, Health and Safety","value":71},{"name":"FDA and Life Sciences","value":21},{"name":"Government Advocacy and Public Policy","value":23},{"name":"Government Contracts","value":116},{"name":"Healthcare","value":24},{"name":"Innovation Protection","value":135},{"name":"International Trade","value":25},{"name":"National Security and Corporate Espionage","value":110},{"name":"Securities Enforcement and Regulation","value":20},{"name":"Special Matters and Government Investigations","value":11},{"name":"Trial and Global Disputes","value":"cg-3"},{"name":"Antitrust ","value":129},{"name":"Appellate, Constitutional and Administrative Law","value":2},{"name":"Bankruptcy and Insolvency Litigation","value":38},{"name":"Class Action Defense","value":3},{"name":"Commercial Litigation","value":5},{"name":"Corporate and Securities Litigation","value":19},{"name":"E-Discovery","value":7},{"name":"Global Construction and Infrastructure Disputes","value":4},{"name":"Innovation Protection","value":136},{"name":"Intellectual Property","value":13},{"name":"International Arbitration and Litigation","value":14},{"name":"Labor and Employment","value":15},{"name":"Product Liability","value":17},{"name":"Professional Liability","value":18},{"name":"Toxic \u0026 Environmental Torts","value":16},{"name":"Industries / Issues","value":"cg-4"},{"name":"Artificial Intelligence (AI) and Machine Learning","value":133},{"name":"Automotive, Transportation and Mobility","value":106},{"name":"Buy American","value":124},{"name":"Crisis Management","value":111},{"name":"Doing Business in Latin America","value":132},{"name":"Energy Transition","value":131},{"name":"Energy","value":102},{"name":"Environmental Agenda","value":125},{"name":"Environmental, Social and Governance (ESG)","value":127},{"name":"Financial Services","value":107},{"name":"Focus on Women's Health","value":112},{"name":"Food and Beverage","value":105},{"name":"Higher Education","value":109},{"name":"Life Sciences and Healthcare","value":103},{"name":"Russia/Ukraine","value":128},{"name":"Special Purpose Acquisition Companies (SPACs)","value":123},{"name":"Technology","value":118}]},"title_id":null,"school_id":null,"office_id":null,"capability_id":"23","extra_filter_id":null,"extra_filter_type":null,"q":null,"starts_with":"L","per_page":12,"people":[{"id":447120,"version":1,"owner_type":"Person","owner_id":6384,"payload":{"bio":"\u003cp\u003eJ. Philip Ludvigson is a partner in King \u0026amp; Spalding\u0026rsquo;s International Trade Group, where he advises clients on national security risks related to foreign direct investment. Phil has held senior roles within the U.S. Departments of Treasury and Homeland Security and draws on his extensive experience to guide clients in resolving a variety of matters, including those related to the Committee on Foreign Investment in the United States (CFIUS) and the Committee for the Assessment of Foreign Participation in the United States Telecommunications Services Sector, otherwise known as \u0026ldquo;Team Telecom.\u0026rdquo;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003ePrior to joining King \u0026amp; Spalding, Phil was the Acting Deputy Assistant Secretary for Investment Security at the U.S. Department of the Treasury. He also served as the Director for Monitoring \u0026amp; Enforcement\u0026mdash;the first person in Treasury\u0026rsquo;s history ever to hold that role\u0026mdash;and built the office that pursues CFIUS non-notified transactions and oversees all CFIUS mitigation measures, including compliance monitoring and enforcement actions. Phil also coordinated Treasury\u0026rsquo;s advisory role in Team Telecom. Before joining Treasury, Phil held various roles at the Department of Homeland Security (DHS), including serving as the Acting Director of Foreign Investment Risk Management, where he led all aspects of the agency\u0026rsquo;s participation in CFIUS and Team Telecom, and as Senior Counsel at the Transportation Security Administration (TSA). He also practiced law for several years in the Washington, D.C. office of an AmLaw 50 firm, focusing on government contracts, security clearances, and Foreign Ownership, Control, or Influence issues. Phil is also a retired Army Reserve officer and combat veteran and was the Production Editor of the\u0026nbsp;University of Illinois\u0026nbsp;\u003cem\u003eJournal of Law, Technology \u0026amp; Policy\u003c/em\u003e\u0026nbsp;in law school.\u003c/p\u003e\n\u003cp\u003eHaving overseen the entire lifecycle of U.S. national security reviews of in-bound investment for both CFIUS and Team Telecom matters, Phil now focuses his practice on providing strategic advice for clients seeking to identify and address potential jurisdiction and risk-related concerns as they structure investments and other business transactions, as well as guiding them through the filing process and mitigation compliance. He also advises clients in a variety of other emerging national security regulatory areas, including supply chain initiatives, transportation and critical infrastructure, and government contracts.\u003c/p\u003e","slug":"j-ludvigson","email":"pludvigson@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":25,"guid":"25.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":110,"guid":"110.capabilities","index":2,"source":"capabilities"},{"id":116,"guid":"116.capabilities","index":3,"source":"capabilities"},{"id":23,"guid":"23.capabilities","index":4,"source":"capabilities"},{"id":1141,"guid":"1141.smart_tags","index":5,"source":"smartTags"},{"id":118,"guid":"118.capabilities","index":6,"source":"capabilities"},{"id":1147,"guid":"1147.smart_tags","index":7,"source":"smartTags"},{"id":1142,"guid":"1142.smart_tags","index":8,"source":"smartTags"},{"id":106,"guid":"106.capabilities","index":9,"source":"capabilities"},{"id":1114,"guid":"1114.smart_tags","index":10,"source":"smartTags"},{"id":102,"guid":"102.capabilities","index":11,"source":"capabilities"},{"id":826,"guid":"826.smart_tags","index":12,"source":"smartTags"},{"id":103,"guid":"103.capabilities","index":13,"source":"capabilities"},{"id":761,"guid":"761.smart_tags","index":14,"source":"smartTags"},{"id":107,"guid":"107.capabilities","index":15,"source":"capabilities"},{"id":1178,"guid":"1178.smart_tags","index":16,"source":"smartTags"},{"id":1220,"guid":"1220.smart_tags","index":17,"source":"smartTags"},{"id":579,"guid":"579.smart_tags","index":18,"source":"smartTags"},{"id":579,"guid":"579.smart_tags","index":19,"source":"smartTags"},{"id":1148,"guid":"1148.smart_tags","index":20,"source":"smartTags"}],"is_active":true,"last_name":"Ludvigson","nick_name":"","clerkships":[],"first_name":"J.","title_rank":9999,"updated_by":202,"law_schools":[{"id":2204,"meta":{"degree":"J.D.","honors":"cum laude","is_law_school":"1","graduation_date":"2006-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"Philip","name_suffix":"","recognitions":[{"title":"Appointed to American Conference Institute's (ACI) National CFIUS Advisory Board (NCAB) ","detail":"ACI, 2025"},{"title":"Named Top Advisor for Foreign Investment and National Security","detail":"Foreign Investment Watch 2023-2026"}],"linked_in_url":"https://www.linkedin.com/in/j-philip-ludvigson-9986233/","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eJ. Philip Ludvigson is a partner in King \u0026amp; Spalding\u0026rsquo;s International Trade Group, where he advises clients on national security risks related to foreign direct investment. Phil has held senior roles within the U.S. Departments of Treasury and Homeland Security and draws on his extensive experience to guide clients in resolving a variety of matters, including those related to the Committee on Foreign Investment in the United States (CFIUS) and the Committee for the Assessment of Foreign Participation in the United States Telecommunications Services Sector, otherwise known as \u0026ldquo;Team Telecom.\u0026rdquo;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003ePrior to joining King \u0026amp; Spalding, Phil was the Acting Deputy Assistant Secretary for Investment Security at the U.S. Department of the Treasury. He also served as the Director for Monitoring \u0026amp; Enforcement\u0026mdash;the first person in Treasury\u0026rsquo;s history ever to hold that role\u0026mdash;and built the office that pursues CFIUS non-notified transactions and oversees all CFIUS mitigation measures, including compliance monitoring and enforcement actions. Phil also coordinated Treasury\u0026rsquo;s advisory role in Team Telecom. Before joining Treasury, Phil held various roles at the Department of Homeland Security (DHS), including serving as the Acting Director of Foreign Investment Risk Management, where he led all aspects of the agency\u0026rsquo;s participation in CFIUS and Team Telecom, and as Senior Counsel at the Transportation Security Administration (TSA). He also practiced law for several years in the Washington, D.C. office of an AmLaw 50 firm, focusing on government contracts, security clearances, and Foreign Ownership, Control, or Influence issues. Phil is also a retired Army Reserve officer and combat veteran and was the Production Editor of the\u0026nbsp;University of Illinois\u0026nbsp;\u003cem\u003eJournal of Law, Technology \u0026amp; Policy\u003c/em\u003e\u0026nbsp;in law school.\u003c/p\u003e\n\u003cp\u003eHaving overseen the entire lifecycle of U.S. national security reviews of in-bound investment for both CFIUS and Team Telecom matters, Phil now focuses his practice on providing strategic advice for clients seeking to identify and address potential jurisdiction and risk-related concerns as they structure investments and other business transactions, as well as guiding them through the filing process and mitigation compliance. He also advises clients in a variety of other emerging national security regulatory areas, including supply chain initiatives, transportation and critical infrastructure, and government contracts.\u003c/p\u003e","recognitions":[{"title":"Appointed to American Conference Institute's (ACI) National CFIUS Advisory Board (NCAB) ","detail":"ACI, 2025"},{"title":"Named Top Advisor for Foreign Investment and National Security","detail":"Foreign Investment Watch 2023-2026"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":9871},{"id":9871}]},"capability_group_id":2},"created_at":"2026-03-30T18:58:13.000Z","updated_at":"2026-03-30T18:58:13.000Z","searchable_text":"Ludvigson{{ FIELD }}{:title=\u0026gt;\"Appointed to American Conference Institute's (ACI) National CFIUS Advisory Board (NCAB) \", :detail=\u0026gt;\"ACI, 2025\"}{{ FIELD }}{:title=\u0026gt;\"Named Top Advisor for Foreign Investment and National Security\", :detail=\u0026gt;\"Foreign Investment Watch 2023-2026\"}{{ FIELD }}J. Philip Ludvigson is a partner in King \u0026amp; Spalding’s International Trade Group, where he advises clients on national security risks related to foreign direct investment. Phil has held senior roles within the U.S. Departments of Treasury and Homeland Security and draws on his extensive experience to guide clients in resolving a variety of matters, including those related to the Committee on Foreign Investment in the United States (CFIUS) and the Committee for the Assessment of Foreign Participation in the United States Telecommunications Services Sector, otherwise known as “Team Telecom.”\nPrior to joining King \u0026amp; Spalding, Phil was the Acting Deputy Assistant Secretary for Investment Security at the U.S. Department of the Treasury. He also served as the Director for Monitoring \u0026amp; Enforcement—the first person in Treasury’s history ever to hold that role—and built the office that pursues CFIUS non-notified transactions and oversees all CFIUS mitigation measures, including compliance monitoring and enforcement actions. Phil also coordinated Treasury’s advisory role in Team Telecom. Before joining Treasury, Phil held various roles at the Department of Homeland Security (DHS), including serving as the Acting Director of Foreign Investment Risk Management, where he led all aspects of the agency’s participation in CFIUS and Team Telecom, and as Senior Counsel at the Transportation Security Administration (TSA). He also practiced law for several years in the Washington, D.C. office of an AmLaw 50 firm, focusing on government contracts, security clearances, and Foreign Ownership, Control, or Influence issues. Phil is also a retired Army Reserve officer and combat veteran and was the Production Editor of the University of Illinois Journal of Law, Technology \u0026amp; Policy in law school.\nHaving overseen the entire lifecycle of U.S. national security reviews of in-bound investment for both CFIUS and Team Telecom matters, Phil now focuses his practice on providing strategic advice for clients seeking to identify and address potential jurisdiction and risk-related concerns as they structure investments and other business transactions, as well as guiding them through the filing process and mitigation compliance. He also advises clients in a variety of other emerging national security regulatory areas, including supply chain initiatives, transportation and critical infrastructure, and government contracts. Partner Appointed to American Conference Institute's (ACI) National CFIUS Advisory Board (NCAB)  ACI, 2025 Named Top Advisor for Foreign Investment and National Security Foreign Investment Watch 2023-2026 American University Washington College of Law University of Illinois at Urbana-Champaign University of Illinois College of Law U.S. Court of Appeals for the Federal Circuit Supreme Court of the United States U.S. Court of Appeals for the D.C. Circuit U.S. Court of Federal Claims District of Columbia Virginia Supreme Court of Virginia","searchable_name":"J. Philip Ludvigson","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":426315,"version":1,"owner_type":"Person","owner_id":2380,"payload":{"bio":"\u003cp\u003eSeth Lundy represents prominent medical device and pharmaceutical companies and healthcare providers, suppliers and distributors in complex legal and regulatory matters and investigations. As Deputy Chair of our FDA and Life Sciences practice, Seth is widely recognized as a leading national authority on compliance with federal and state fraud and abuse laws. His practical, business-oriented approach earns accolades as one of the industry's leading lawyers from sources including \u003cem\u003eChambers USA\u003c/em\u003e, LMG Life Sciences, Legal 500,\u0026nbsp;\u003cem\u003eBest Lawyers,\u003c/em\u003e and \u003cem\u003eSuper Lawyers\u003c/em\u003e.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eSeth's in-depth understanding of the industry allows him to work seamlessly with boards of directors, C-suite management, legal departments, compliance offices and operational divisions. He designs compliance programs; helps client to ensure that operations meet changing standards; defends clients in government investigations; performs internal audits; conducts corporate due diligence; and engages in civil, criminal and administrative litigation.\u003c/p\u003e\n\u003cp\u003eSeth is experienced in working with federal regulators and legislators to create, revise and interpret healthcare-related laws, regulations and policies. He also develops business and marketing strategies that respond to ever-changing federal regulatory schemes.\u003c/p\u003e\n\u003cp\u003eA frequent author and speaker on healthcare compliance and investigations, Seth works to help clients to identify and predict burgeoning areas of enforcement. Seth has been recognized since 2008 as a top Washington, D.C. healthcare lawyer by \u003cem\u003eChambers USA\u003c/em\u003e. He has also received recognition as a leading healthcare lawyer from \u003cem\u003eExpert Guides, Guide to the Leading Healthcare Lawyers,\u003c/em\u003e Super Lawyers Washington, D.C.\u003cem\u003e,\u003c/em\u003e \u003cem\u003eBest Lawyers\u003c/em\u003e, and \u003cem\u003eWashingtonian Magazine\u003c/em\u003e's Top Lawyers rankings.\u003c/p\u003e","slug":"seth-lundy","email":"slundy@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":2,"guid":"2.capabilities","index":0,"source":"capabilities"},{"id":6,"guid":"6.capabilities","index":1,"source":"capabilities"},{"id":7,"guid":"7.capabilities","index":2,"source":"capabilities"},{"id":23,"guid":"23.capabilities","index":3,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":4,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":5,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":6,"source":"capabilities"},{"id":32,"guid":"32.capabilities","index":7,"source":"capabilities"},{"id":761,"guid":"761.smart_tags","index":8,"source":"smartTags"},{"id":33,"guid":"33.capabilities","index":9,"source":"capabilities"},{"id":17,"guid":"17.capabilities","index":10,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":11,"source":"capabilities"},{"id":80,"guid":"80.capabilities","index":12,"source":"capabilities"},{"id":970,"guid":"970.smart_tags","index":13,"source":"smartTags"},{"id":109,"guid":"109.capabilities","index":14,"source":"capabilities"},{"id":1097,"guid":"1097.smart_tags","index":15,"source":"smartTags"},{"id":110,"guid":"110.capabilities","index":16,"source":"capabilities"},{"id":112,"guid":"112.capabilities","index":17,"source":"capabilities"},{"id":120,"guid":"120.capabilities","index":18,"source":"capabilities"},{"id":122,"guid":"122.capabilities","index":19,"source":"capabilities"},{"id":1199,"guid":"1199.smart_tags","index":20,"source":"smartTags"},{"id":1193,"guid":"1193.smart_tags","index":21,"source":"smartTags"},{"id":1202,"guid":"1202.smart_tags","index":22,"source":"smartTags"},{"id":1223,"guid":"1223.smart_tags","index":23,"source":"smartTags"},{"id":133,"guid":"133.capabilities","index":24,"source":"capabilities"}],"is_active":true,"last_name":"Lundy","nick_name":"Seth","clerkships":[],"first_name":"Seth","title_rank":9999,"updated_by":174,"law_schools":[],"middle_name":"H.","name_suffix":"","recognitions":[{"title":"Top Healthcare Lawyer: Washington, D.C. ","detail":"Chambers USA"},{"title":"Leading Healthcare Lawyer","detail":"Expert Guides and Guide to the Leading Healthcare Lawyers"},{"title":"Super Lawyers: Washington, D.C.","detail":""},{"title":"The Best Lawyers in America","detail":""},{"title":"Top Lawyers ","detail":"Washingtonian Magazine"},{"title":"Named to Best Lawyers in America for FDA Law","detail":"Best Lawyers in America, 2020"}],"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eSeth Lundy represents prominent medical device and pharmaceutical companies and healthcare providers, suppliers and distributors in complex legal and regulatory matters and investigations. As Deputy Chair of our FDA and Life Sciences practice, Seth is widely recognized as a leading national authority on compliance with federal and state fraud and abuse laws. His practical, business-oriented approach earns accolades as one of the industry's leading lawyers from sources including \u003cem\u003eChambers USA\u003c/em\u003e, LMG Life Sciences, Legal 500,\u0026nbsp;\u003cem\u003eBest Lawyers,\u003c/em\u003e and \u003cem\u003eSuper Lawyers\u003c/em\u003e.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eSeth's in-depth understanding of the industry allows him to work seamlessly with boards of directors, C-suite management, legal departments, compliance offices and operational divisions. He designs compliance programs; helps client to ensure that operations meet changing standards; defends clients in government investigations; performs internal audits; conducts corporate due diligence; and engages in civil, criminal and administrative litigation.\u003c/p\u003e\n\u003cp\u003eSeth is experienced in working with federal regulators and legislators to create, revise and interpret healthcare-related laws, regulations and policies. He also develops business and marketing strategies that respond to ever-changing federal regulatory schemes.\u003c/p\u003e\n\u003cp\u003eA frequent author and speaker on healthcare compliance and investigations, Seth works to help clients to identify and predict burgeoning areas of enforcement. Seth has been recognized since 2008 as a top Washington, D.C. healthcare lawyer by \u003cem\u003eChambers USA\u003c/em\u003e. He has also received recognition as a leading healthcare lawyer from \u003cem\u003eExpert Guides, Guide to the Leading Healthcare Lawyers,\u003c/em\u003e Super Lawyers Washington, D.C.\u003cem\u003e,\u003c/em\u003e \u003cem\u003eBest Lawyers\u003c/em\u003e, and \u003cem\u003eWashingtonian Magazine\u003c/em\u003e's Top Lawyers rankings.\u003c/p\u003e","recognitions":[{"title":"Top Healthcare Lawyer: Washington, D.C. ","detail":"Chambers USA"},{"title":"Leading Healthcare Lawyer","detail":"Expert Guides and Guide to the Leading Healthcare Lawyers"},{"title":"Super Lawyers: Washington, D.C.","detail":""},{"title":"The Best Lawyers in America","detail":""},{"title":"Top Lawyers ","detail":"Washingtonian Magazine"},{"title":"Named to Best Lawyers in America for FDA Law","detail":"Best Lawyers in America, 2020"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":1020}]},"capability_group_id":2},"created_at":"2025-05-26T04:50:49.000Z","updated_at":"2025-05-26T04:50:49.000Z","searchable_text":"Lundy{{ FIELD }}{:title=\u0026gt;\"Top Healthcare Lawyer: Washington, D.C. \", :detail=\u0026gt;\"Chambers USA\"}{{ FIELD }}{:title=\u0026gt;\"Leading Healthcare Lawyer\", :detail=\u0026gt;\"Expert Guides and Guide to the Leading Healthcare Lawyers\"}{{ FIELD }}{:title=\u0026gt;\"Super Lawyers: Washington, D.C.\", :detail=\u0026gt;\"\"}{{ FIELD }}{:title=\u0026gt;\"The Best Lawyers in America\", :detail=\u0026gt;\"\"}{{ FIELD }}{:title=\u0026gt;\"Top Lawyers \", :detail=\u0026gt;\"Washingtonian Magazine\"}{{ FIELD }}{:title=\u0026gt;\"Named to Best Lawyers in America for FDA Law\", :detail=\u0026gt;\"Best Lawyers in America, 2020\"}{{ FIELD }}Seth Lundy represents prominent medical device and pharmaceutical companies and healthcare providers, suppliers and distributors in complex legal and regulatory matters and investigations. As Deputy Chair of our FDA and Life Sciences practice, Seth is widely recognized as a leading national authority on compliance with federal and state fraud and abuse laws. His practical, business-oriented approach earns accolades as one of the industry's leading lawyers from sources including Chambers USA, LMG Life Sciences, Legal 500, Best Lawyers, and Super Lawyers.\nSeth's in-depth understanding of the industry allows him to work seamlessly with boards of directors, C-suite management, legal departments, compliance offices and operational divisions. He designs compliance programs; helps client to ensure that operations meet changing standards; defends clients in government investigations; performs internal audits; conducts corporate due diligence; and engages in civil, criminal and administrative litigation.\nSeth is experienced in working with federal regulators and legislators to create, revise and interpret healthcare-related laws, regulations and policies. He also develops business and marketing strategies that respond to ever-changing federal regulatory schemes.\nA frequent author and speaker on healthcare compliance and investigations, Seth works to help clients to identify and predict burgeoning areas of enforcement. Seth has been recognized since 2008 as a top Washington, D.C. healthcare lawyer by Chambers USA. He has also received recognition as a leading healthcare lawyer from Expert Guides, Guide to the Leading Healthcare Lawyers, Super Lawyers Washington, D.C., Best Lawyers, and Washingtonian Magazine's Top Lawyers rankings. Partner Top Healthcare Lawyer: Washington, D.C.  Chambers USA Leading Healthcare Lawyer Expert Guides and Guide to the Leading Healthcare Lawyers Super Lawyers: Washington, D.C.  The Best Lawyers in America  Top Lawyers  Washingtonian Magazine Named to Best Lawyers in America for FDA Law Best Lawyers in America, 2020 Amherst College  George Washington University George Washington University Law School District of Columbia Maryland","searchable_name":"Seth H. Lundy","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":174,"capability_group_featured":null,"home_page_featured":null},{"id":436487,"version":1,"owner_type":"Person","owner_id":5154,"payload":{"bio":"\u003cp\u003eDan Lungren is senior counsel in the firm\u0026rsquo;s Government Advocacy and Public Policy group. As a former U.S. Congressman and California State Attorney General, he is widely respected as an individual of the highest integrity and ethics with strong personal relationships on both sides of the aisle. Dan\u0026rsquo;s deep substantive knowledge and familiarity with the legislative and executive processes and people that make government work allows him to provide unique counsel to clients on a wide range of matters pending before Congress, the executive branch and state attorneys general across the country.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eHon. Dan Lungren\u0026nbsp;served nine terms as a member of the U.S. House of Representatives and two terms as California\u0026rsquo;s Attorney General.\u0026nbsp; In the Congress he represented both southern California (including the counties of Los Angeles and Orange) from 1979-89 and northern California (including the county of Sacramento) from 2005-13.\u003c/p\u003e\n\u003cp\u003eA member of the House Judiciary Committee for eighteen years, Dan specialized in the issues of crime, immigration and national security.\u0026nbsp; In that capacity he was involved in the active oversight of the U.S. Department of Justice.\u0026nbsp; Additionally, Lungren served on the House Intelligence and Budget Committees, was a senior member of the House Committee on Homeland Security and chairman of the Subcommittee on Cybersecurity and Critical Infrastructure.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eA national leader on criminal justice issues, he was recognized by his peers in the National Association of Attorneys General with the Wyman Award as the best attorney general in the nation.\u0026nbsp;His leadership as California\u0026rsquo;s \u0026rdquo;Top Cop\u0026rdquo; resulted in a crime drop of 30% with a homicide drop of 50%.\u0026nbsp; Dan successfully argued a case before the U.S. Supreme Court.\u0026nbsp; \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eDan is a graduate of the University of Notre Dame, attended law school at the University of Southern California and graduated from Georgetown University Law Center with his J.D.\u0026nbsp;\u0026nbsp;\u003c/p\u003e","slug":"daniel-lungren","email":"dlungren@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":23,"guid":"23.capabilities","index":0,"source":"capabilities"},{"id":6,"guid":"6.capabilities","index":1,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":2,"source":"capabilities"},{"id":11,"guid":"11.capabilities","index":3,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":4,"source":"capabilities"},{"id":750,"guid":"750.smart_tags","index":5,"source":"smartTags"}],"is_active":true,"last_name":"Lungren","nick_name":"Daniel","clerkships":[],"first_name":"Daniel","title_rank":9999,"updated_by":24,"law_schools":[{"id":755,"meta":{"degree":"J.D.","honors":null,"is_law_school":1,"graduation_date":"1971-01-01 00:00:00 UTC"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"E.","name_suffix":"","recognitions":null,"linked_in_url":"https://www.linkedin.com/in/danlungren/","seodescription":null,"primary_title_id":77,"translated_fields":{"en":{"bio":"\u003cp\u003eDan Lungren is senior counsel in the firm\u0026rsquo;s Government Advocacy and Public Policy group. As a former U.S. Congressman and California State Attorney General, he is widely respected as an individual of the highest integrity and ethics with strong personal relationships on both sides of the aisle. Dan\u0026rsquo;s deep substantive knowledge and familiarity with the legislative and executive processes and people that make government work allows him to provide unique counsel to clients on a wide range of matters pending before Congress, the executive branch and state attorneys general across the country.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eHon. Dan Lungren\u0026nbsp;served nine terms as a member of the U.S. House of Representatives and two terms as California\u0026rsquo;s Attorney General.\u0026nbsp; In the Congress he represented both southern California (including the counties of Los Angeles and Orange) from 1979-89 and northern California (including the county of Sacramento) from 2005-13.\u003c/p\u003e\n\u003cp\u003eA member of the House Judiciary Committee for eighteen years, Dan specialized in the issues of crime, immigration and national security.\u0026nbsp; In that capacity he was involved in the active oversight of the U.S. Department of Justice.\u0026nbsp; Additionally, Lungren served on the House Intelligence and Budget Committees, was a senior member of the House Committee on Homeland Security and chairman of the Subcommittee on Cybersecurity and Critical Infrastructure.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eA national leader on criminal justice issues, he was recognized by his peers in the National Association of Attorneys General with the Wyman Award as the best attorney general in the nation.\u0026nbsp;His leadership as California\u0026rsquo;s \u0026rdquo;Top Cop\u0026rdquo; resulted in a crime drop of 30% with a homicide drop of 50%.\u0026nbsp; Dan successfully argued a case before the U.S. Supreme Court.\u0026nbsp; \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eDan is a graduate of the University of Notre Dame, attended law school at the University of Southern California and graduated from Georgetown University Law Center with his J.D.\u0026nbsp;\u0026nbsp;\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":5783}]},"capability_group_id":2},"created_at":"2025-09-02T04:55:48.000Z","updated_at":"2025-09-02T04:55:48.000Z","searchable_text":"Lungren{{ FIELD }}Dan Lungren is senior counsel in the firm’s Government Advocacy and Public Policy group. As a former U.S. Congressman and California State Attorney General, he is widely respected as an individual of the highest integrity and ethics with strong personal relationships on both sides of the aisle. Dan’s deep substantive knowledge and familiarity with the legislative and executive processes and people that make government work allows him to provide unique counsel to clients on a wide range of matters pending before Congress, the executive branch and state attorneys general across the country.\nHon. Dan Lungren served nine terms as a member of the U.S. House of Representatives and two terms as California’s Attorney General.  In the Congress he represented both southern California (including the counties of Los Angeles and Orange) from 1979-89 and northern California (including the county of Sacramento) from 2005-13.\nA member of the House Judiciary Committee for eighteen years, Dan specialized in the issues of crime, immigration and national security.  In that capacity he was involved in the active oversight of the U.S. Department of Justice.  Additionally, Lungren served on the House Intelligence and Budget Committees, was a senior member of the House Committee on Homeland Security and chairman of the Subcommittee on Cybersecurity and Critical Infrastructure. \nA national leader on criminal justice issues, he was recognized by his peers in the National Association of Attorneys General with the Wyman Award as the best attorney general in the nation. His leadership as California’s ”Top Cop” resulted in a crime drop of 30% with a homicide drop of 50%.  Dan successfully argued a case before the U.S. Supreme Court.   \nDan is a graduate of the University of Notre Dame, attended law school at the University of Southern California and graduated from Georgetown University Law Center with his J.D.   Senior Counsel University of Notre Dame Notre Dame Law School Georgetown University Georgetown University Law Center California District of Columbia The Fletcher Jones Foundation, Trustee and Vice Chair Dominican School of Philosophy and Theology, Graduate Theological Union, Member of College of Fellows","searchable_name":"Daniel E. Lungren","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":24,"capability_group_featured":null,"home_page_featured":null},{"id":427684,"version":1,"owner_type":"Person","owner_id":1533,"payload":{"bio":"\u003cp\u003eDr. Beverly Lorell is the Senior Medical and Policy Advisor with the firm\u0026rsquo;s FDA and Life Sciences Practice in Washington, D.C. Dr. Lorell specializes in the areas of clinical trial design of studies for drugs, devices and biologics; review of pre-market submissions; recalls; and assessment of matters involving a risk to health. She also specializes in the area of physician and industry relations and the development of independent scientific panels to advise health industries.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eDr. Lorell,\u0026nbsp;who was previously Professor of Medicine at Harvard University, has over twenty-five years of experience as a practicing interventional cardiologist and heart failure specialist. She is an internationally recognized clinical and basic science investigator with extensive experience in multi-center clinical trials and preclinical proof-of-concept translational science. Prior to joining King \u0026amp; Spalding, Dr. Lorell served as Vice President and global Chief Medical and Technology Officer at Guidant Corporation. There her responsibilities included evaluating emerging technologies and attendant regulatory challenges, determining product development priorities, and influencing clinical research strategies. She participated in the firm\u0026rsquo;s board for business development.\u003c/p\u003e\n\u003cp\u003eDuring her career at Harvard Medical School, she served the federal government in multiple roles including:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eFood and Drug Administration\u0026rsquo;s Cardiovascular and Renal Drugs Advisory Committee. Notable issues included: Irbesartan (preservation of renal function in type 2 diabetes mellitus), Pravastatin/aspirin combination (can combination be justified based on meta-analysis in absence of specific trial data supporting the combination), Losartan (nephropathy in type 2 diabetes), Candesartan (blood pressure reduction in comparison with Losartan), Omapatrilat (balancing benefit of new antihypertensive vs risk of angioedema), Ranolazine - an antianginal, Alfuzosin- erectile dysfunction, and Verdenafil - prostatic hypertrophy (balancing drug benefits vs. risks of QT interval prolongation), Ximelagatran (balancing benefits of new antithrombotic vs. risks of hepatotoxicity),\u003c/li\u003e\n\u003cli\u003eFederally funded investigator of the National Institutes of Health,\u003c/li\u003e\n\u003cli\u003eNational task force and special emphasis panels of the National Institutes of Health, and\u003c/li\u003e\n\u003cli\u003eThe Cardiovascular Study Section of the National Heart, Lung, and Blood Institute of the National Institutes of Health.\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003eDr. Lorell\u0026nbsp;has served in national leadership positions in professional societies. She was an Established Investigator of the American Heart Association (AHA). Additional honors include election as Fellow of the American College of Cardiology (FACC) and the American Heart Association (FAHA) and founding member of the Heart Failure Society of America. She served on the Executive Committees of both the Council on Clinical Cardiology and the Council on Basic Science of the AHA. Recent national leadership roles included the national Executive Committee of the Task Force on Clinical Competence of the ACC, AHA and American College of Physicians, a body which determines national standards for medical competency for novel cardiovascular technologies. She was also a member of the Consensus Conference Group on Professionalism and Ethics of the ACC and AHA. She continues to be an active invited lecturer at national professional meetings, as well as Harvard Law School and Harvard Medical School.\u003c/p\u003e\n\u003cp\u003eShe now represents King \u0026amp; Spalding as a member of the Executive Committee of the New England Healthcare Institute, a nonprofit health policy organization, and as a member of the Steering Committee of the Clinical Trials Transformation Initiative, a public-private initiative between FDA, academic centers, and industry.\u003c/p\u003e\n\u003cp\u003eDr. Lorell\u0026nbsp;is a graduate of Stanford University, and she received her M.D. degree and her Residency in Internal Medicine from Stanford University Medical School. She received her advanced training as a Fellow in Cardiovascular Medicine at Harvard University. She is a Diplomate of the American Board of Internal Medicine, the Subspecialty Board of Cardiovascular Disease, and the Subspecialty Board of Interventional Cardiology. She is admitted to practice medicine in the states of California and Massachusetts. She is the author of over 160 medical science publications, 26 chapters and 2 books, including 8 recent publications in the area of health policy. Edward M. Basile, Partner at King \u0026amp; Spalding, and Dr. Lorell are authors of the recent publication, \u003cem\u003eThe Food and Drug Administration\u0026rsquo;s Regulation of Risk Disclosure for Implantable Cardioverter Defibrillators: Has Technology Outpaced the Agency\u0026rsquo;s Regulatory Framework?, \u003c/em\u003e61 FOOD AND DRUG LAW JOURNAL 251-272 (2006).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eRecent Publications\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eCo-author, \u003cem\u003eThe Food and Drug Administration\u0026rsquo;s Regulation of Risk Disclosure for Implantable Cardioverter Defibrillators: Has Technology Outpaced the Agency\u0026rsquo;s Regulatory Framework?, \u003c/em\u003e61 FOOD AND DRUG LAW JOURNAL 251-272 (2006)\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u003cstrong\u003eMemberships\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eEstablished Investigator of the American Heart Association (AHA)\u003c/li\u003e\n\u003cli\u003eFellow of the American College of Cardiology (FACC)\u003c/li\u003e\n\u003cli\u003eFellow of the American Heart Association (FAHA)\u003c/li\u003e\n\u003cli\u003eFounding Member of the Heart Failure Society of America\u003c/li\u003e\n\u003cli\u003eCouncil on Clinical Cardiology, Executive Committee\u003c/li\u003e\n\u003cli\u003eCouncil on Basic Science of the AHA, Executive Committee\u003c/li\u003e\n\u003cli\u003eExecutive Committee of the Task Force on Clinical Competence of the ACC, AHA and American College of Physicians\u003c/li\u003e\n\u003cli\u003eConsensus Conference Group on Professionalism and Ethics of the ACC and AHA\u003c/li\u003e\n\u003cli\u003eAmerican Board of Internal Medicine, Diplomate\u003c/li\u003e\n\u003cli\u003eSubspecialty Board of Cardiovascular Disease\u003c/li\u003e\n\u003cli\u003eSubspecialty Board of Interventional Cardiology\u003c/li\u003e\n\u003c/ul\u003e","slug":"bev-lorell","email":"blorell@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":23,"guid":"23.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":2,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":3,"source":"capabilities"}],"is_active":true,"last_name":"Lorell","nick_name":"Beverly","clerkships":[],"first_name":"Bev","title_rank":9999,"updated_by":101,"law_schools":[],"middle_name":"H.","name_suffix":"M.D.","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":11,"translated_fields":{"en":{"bio":"\u003cp\u003eDr. Beverly Lorell is the Senior Medical and Policy Advisor with the firm\u0026rsquo;s FDA and Life Sciences Practice in Washington, D.C. Dr. Lorell specializes in the areas of clinical trial design of studies for drugs, devices and biologics; review of pre-market submissions; recalls; and assessment of matters involving a risk to health. She also specializes in the area of physician and industry relations and the development of independent scientific panels to advise health industries.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eDr. Lorell,\u0026nbsp;who was previously Professor of Medicine at Harvard University, has over twenty-five years of experience as a practicing interventional cardiologist and heart failure specialist. She is an internationally recognized clinical and basic science investigator with extensive experience in multi-center clinical trials and preclinical proof-of-concept translational science. Prior to joining King \u0026amp; Spalding, Dr. Lorell served as Vice President and global Chief Medical and Technology Officer at Guidant Corporation. There her responsibilities included evaluating emerging technologies and attendant regulatory challenges, determining product development priorities, and influencing clinical research strategies. She participated in the firm\u0026rsquo;s board for business development.\u003c/p\u003e\n\u003cp\u003eDuring her career at Harvard Medical School, she served the federal government in multiple roles including:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eFood and Drug Administration\u0026rsquo;s Cardiovascular and Renal Drugs Advisory Committee. Notable issues included: Irbesartan (preservation of renal function in type 2 diabetes mellitus), Pravastatin/aspirin combination (can combination be justified based on meta-analysis in absence of specific trial data supporting the combination), Losartan (nephropathy in type 2 diabetes), Candesartan (blood pressure reduction in comparison with Losartan), Omapatrilat (balancing benefit of new antihypertensive vs risk of angioedema), Ranolazine - an antianginal, Alfuzosin- erectile dysfunction, and Verdenafil - prostatic hypertrophy (balancing drug benefits vs. risks of QT interval prolongation), Ximelagatran (balancing benefits of new antithrombotic vs. risks of hepatotoxicity),\u003c/li\u003e\n\u003cli\u003eFederally funded investigator of the National Institutes of Health,\u003c/li\u003e\n\u003cli\u003eNational task force and special emphasis panels of the National Institutes of Health, and\u003c/li\u003e\n\u003cli\u003eThe Cardiovascular Study Section of the National Heart, Lung, and Blood Institute of the National Institutes of Health.\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003eDr. Lorell\u0026nbsp;has served in national leadership positions in professional societies. She was an Established Investigator of the American Heart Association (AHA). Additional honors include election as Fellow of the American College of Cardiology (FACC) and the American Heart Association (FAHA) and founding member of the Heart Failure Society of America. She served on the Executive Committees of both the Council on Clinical Cardiology and the Council on Basic Science of the AHA. Recent national leadership roles included the national Executive Committee of the Task Force on Clinical Competence of the ACC, AHA and American College of Physicians, a body which determines national standards for medical competency for novel cardiovascular technologies. She was also a member of the Consensus Conference Group on Professionalism and Ethics of the ACC and AHA. She continues to be an active invited lecturer at national professional meetings, as well as Harvard Law School and Harvard Medical School.\u003c/p\u003e\n\u003cp\u003eShe now represents King \u0026amp; Spalding as a member of the Executive Committee of the New England Healthcare Institute, a nonprofit health policy organization, and as a member of the Steering Committee of the Clinical Trials Transformation Initiative, a public-private initiative between FDA, academic centers, and industry.\u003c/p\u003e\n\u003cp\u003eDr. Lorell\u0026nbsp;is a graduate of Stanford University, and she received her M.D. degree and her Residency in Internal Medicine from Stanford University Medical School. She received her advanced training as a Fellow in Cardiovascular Medicine at Harvard University. She is a Diplomate of the American Board of Internal Medicine, the Subspecialty Board of Cardiovascular Disease, and the Subspecialty Board of Interventional Cardiology. She is admitted to practice medicine in the states of California and Massachusetts. She is the author of over 160 medical science publications, 26 chapters and 2 books, including 8 recent publications in the area of health policy. Edward M. Basile, Partner at King \u0026amp; Spalding, and Dr. Lorell are authors of the recent publication, \u003cem\u003eThe Food and Drug Administration\u0026rsquo;s Regulation of Risk Disclosure for Implantable Cardioverter Defibrillators: Has Technology Outpaced the Agency\u0026rsquo;s Regulatory Framework?, \u003c/em\u003e61 FOOD AND DRUG LAW JOURNAL 251-272 (2006).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eRecent Publications\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eCo-author, \u003cem\u003eThe Food and Drug Administration\u0026rsquo;s Regulation of Risk Disclosure for Implantable Cardioverter Defibrillators: Has Technology Outpaced the Agency\u0026rsquo;s Regulatory Framework?, \u003c/em\u003e61 FOOD AND DRUG LAW JOURNAL 251-272 (2006)\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u003cstrong\u003eMemberships\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eEstablished Investigator of the American Heart Association (AHA)\u003c/li\u003e\n\u003cli\u003eFellow of the American College of Cardiology (FACC)\u003c/li\u003e\n\u003cli\u003eFellow of the American Heart Association (FAHA)\u003c/li\u003e\n\u003cli\u003eFounding Member of the Heart Failure Society of America\u003c/li\u003e\n\u003cli\u003eCouncil on Clinical Cardiology, Executive Committee\u003c/li\u003e\n\u003cli\u003eCouncil on Basic Science of the AHA, Executive Committee\u003c/li\u003e\n\u003cli\u003eExecutive Committee of the Task Force on Clinical Competence of the ACC, AHA and American College of Physicians\u003c/li\u003e\n\u003cli\u003eConsensus Conference Group on Professionalism and Ethics of the ACC and AHA\u003c/li\u003e\n\u003cli\u003eAmerican Board of Internal Medicine, Diplomate\u003c/li\u003e\n\u003cli\u003eSubspecialty Board of Cardiovascular Disease\u003c/li\u003e\n\u003cli\u003eSubspecialty Board of Interventional Cardiology\u003c/li\u003e\n\u003c/ul\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":4352}]},"capability_group_id":2},"created_at":"2025-05-26T05:03:44.000Z","updated_at":"2025-05-26T05:03:44.000Z","searchable_text":"Lorell{{ FIELD }}Dr. Beverly Lorell is the Senior Medical and Policy Advisor with the firm’s FDA and Life Sciences Practice in Washington, D.C. Dr. Lorell specializes in the areas of clinical trial design of studies for drugs, devices and biologics; review of pre-market submissions; recalls; and assessment of matters involving a risk to health. She also specializes in the area of physician and industry relations and the development of independent scientific panels to advise health industries. \nDr. Lorell, who was previously Professor of Medicine at Harvard University, has over twenty-five years of experience as a practicing interventional cardiologist and heart failure specialist. She is an internationally recognized clinical and basic science investigator with extensive experience in multi-center clinical trials and preclinical proof-of-concept translational science. Prior to joining King \u0026amp; Spalding, Dr. Lorell served as Vice President and global Chief Medical and Technology Officer at Guidant Corporation. There her responsibilities included evaluating emerging technologies and attendant regulatory challenges, determining product development priorities, and influencing clinical research strategies. She participated in the firm’s board for business development.\nDuring her career at Harvard Medical School, she served the federal government in multiple roles including:\n\nFood and Drug Administration’s Cardiovascular and Renal Drugs Advisory Committee. Notable issues included: Irbesartan (preservation of renal function in type 2 diabetes mellitus), Pravastatin/aspirin combination (can combination be justified based on meta-analysis in absence of specific trial data supporting the combination), Losartan (nephropathy in type 2 diabetes), Candesartan (blood pressure reduction in comparison with Losartan), Omapatrilat (balancing benefit of new antihypertensive vs risk of angioedema), Ranolazine - an antianginal, Alfuzosin- erectile dysfunction, and Verdenafil - prostatic hypertrophy (balancing drug benefits vs. risks of QT interval prolongation), Ximelagatran (balancing benefits of new antithrombotic vs. risks of hepatotoxicity),\nFederally funded investigator of the National Institutes of Health,\nNational task force and special emphasis panels of the National Institutes of Health, and\nThe Cardiovascular Study Section of the National Heart, Lung, and Blood Institute of the National Institutes of Health.\n\nDr. Lorell has served in national leadership positions in professional societies. She was an Established Investigator of the American Heart Association (AHA). Additional honors include election as Fellow of the American College of Cardiology (FACC) and the American Heart Association (FAHA) and founding member of the Heart Failure Society of America. She served on the Executive Committees of both the Council on Clinical Cardiology and the Council on Basic Science of the AHA. Recent national leadership roles included the national Executive Committee of the Task Force on Clinical Competence of the ACC, AHA and American College of Physicians, a body which determines national standards for medical competency for novel cardiovascular technologies. She was also a member of the Consensus Conference Group on Professionalism and Ethics of the ACC and AHA. She continues to be an active invited lecturer at national professional meetings, as well as Harvard Law School and Harvard Medical School.\nShe now represents King \u0026amp; Spalding as a member of the Executive Committee of the New England Healthcare Institute, a nonprofit health policy organization, and as a member of the Steering Committee of the Clinical Trials Transformation Initiative, a public-private initiative between FDA, academic centers, and industry.\nDr. Lorell is a graduate of Stanford University, and she received her M.D. degree and her Residency in Internal Medicine from Stanford University Medical School. She received her advanced training as a Fellow in Cardiovascular Medicine at Harvard University. She is a Diplomate of the American Board of Internal Medicine, the Subspecialty Board of Cardiovascular Disease, and the Subspecialty Board of Interventional Cardiology. She is admitted to practice medicine in the states of California and Massachusetts. She is the author of over 160 medical science publications, 26 chapters and 2 books, including 8 recent publications in the area of health policy. Edward M. Basile, Partner at King \u0026amp; Spalding, and Dr. Lorell are authors of the recent publication, The Food and Drug Administration’s Regulation of Risk Disclosure for Implantable Cardioverter Defibrillators: Has Technology Outpaced the Agency’s Regulatory Framework?, 61 FOOD AND DRUG LAW JOURNAL 251-272 (2006).\nRecent Publications\n\nCo-author, The Food and Drug Administration’s Regulation of Risk Disclosure for Implantable Cardioverter Defibrillators: Has Technology Outpaced the Agency’s Regulatory Framework?, 61 FOOD AND DRUG LAW JOURNAL 251-272 (2006)\n\nMemberships\n\nEstablished Investigator of the American Heart Association (AHA)\nFellow of the American College of Cardiology (FACC)\nFellow of the American Heart Association (FAHA)\nFounding Member of the Heart Failure Society of America\nCouncil on Clinical Cardiology, Executive Committee\nCouncil on Basic Science of the AHA, Executive Committee\nExecutive Committee of the Task Force on Clinical Competence of the ACC, AHA and American College of Physicians\nConsensus Conference Group on Professionalism and Ethics of the ACC and AHA\nAmerican Board of Internal Medicine, Diplomate\nSubspecialty Board of Cardiovascular Disease\nSubspecialty Board of Interventional Cardiology\n Consultant Stanford University Stanford Law School Stanford University Stanford Law School","searchable_name":"Bev H. Lorell, M.D. (Beverly)","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":101,"capability_group_featured":null,"home_page_featured":null}]}}